Massimo Calafiore - 04 Mar 2026 Form 4 Insider Report for Orthofix Medical Inc. (OFIX)

Reporting relationship: President & CEO, Director
Issuer ticker: OFIX
Reported as of: 04 Mar 2026
Net transaction value: -$155,633
SEC form: 4
Accepted by SEC: 06 Mar 2026, 16:17:51 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Andres Cedron, Attorney-in-fact

Key filing fact

Massimo Calafiore filed Form 4 for Orthofix Medical Inc. (OFIX) on 06 Mar 2026.

Key facts

This page summarizes Massimo Calafiore's Form 4 filing for Orthofix Medical Inc. (OFIX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Mar 2026, 16:17.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: -$155,633.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001828602 Primary reporting owner

Calafiore Massimo

Relationship: President & CEO, Director
Address: 3451 PLANO PARKWAY, LEWISVILLE
Signature: /s/ J. Andres Cedron, Attorney-in-fact
Signature date: 06 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OFIX transaction

Common Stock

Sale

Transaction value: $79,939
Shares: -6,189
Change %: -1.9%
Price: $12.92
Shares after: 326,167
Date: 04 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3

OFIX transaction

Common Stock

Sale

Transaction value: $75,694
Shares: -6,031
Change %: -1.8%
Price: $12.55
Shares after: 320,136
Date: 05 Mar 2026
Ownership: Direct
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

Footnote F3

Includes 221,042 previously reported restricted stock units.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.